View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Special Focus
  2. Covid-19
April 16, 2021

Real world study finds Pfizer-BioNTech Covid-19 vaccine to be 92% effective

By Paul Dennis

16 April

Shane Oliver, an economist, retweeted an article on a real-world study of more than one million people in Israel, and the effect of the Pfizer-BioNTech Covid-19 vaccine (BNT162b2 mRNA) in a nationwide mass vaccination settling.

The study revealed vaccine effectiveness against the coronavirus infection to be 92%, seven days after being administered the second dose.

Estimated effectiveness in preventing death from Covid-19 was 72% for 14 days through 20 after the first dose.

Effectiveness in specific subgroups of the population assessed for documented infection and symptomatic Covid-19 was consistent across age groups, with slightly lower effectiveness in people with other multiple co-existing conditions.

The study confirmed that the vaccine is effective for a wide range of Covid-19-related outcomes, a finding that is consistent with the results of the randomised trial.

Read more

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU